Medindia

X

Bruker and Agilent Technologies Announce Agreement for Bruker to Acquire Certain Varian, Inc. Product Lines

Thursday, March 11, 2010 General News J E 4
Advertisement
PALO ALTO, Calif., March 9 Varian, Inc. (Nasdaq GS: VARI) announced today that Bruker Corporation (Nasdaq: BRKR) and Agilent Technologies, Inc. (NYSE: A) have entered into a definitive asset purchase agreement pursuant to which Bruker will acquire certain product lines of Varian. As previously announced, Agilent committed to divest those product lines in connection with obtaining regulatory approval for Agilent's pending acquisition of Varian.

The product lines to be acquired by Bruker are:

Agilent and Bruker announced that their transaction is subject to customary closing conditions and regulatory approvals, and is expected to close shortly after Agilent completes its acquisition of Varian (which Agilent anticipates will occur by April 30, 2010, following regulatory approvals).

About Varian, Inc.

Varian, Inc. is a leading worldwide supplier of scientific instruments and vacuum technologies for life science, environmental, energy, and applied research and other applications. The company provides complete solutions, including instruments, vacuum products, laboratory consumable supplies, software, training and support through its global distribution and support systems. Varian, Inc.'s common stock is traded on the NASDAQ Global Select Market under the symbol "VARI." Further information is available on the company's Web site at http://www.varianinc.com.

-- Varian's inductively coupled plasma mass spectrometry (ICP-MS) instruments business; -- Varian's laboratory gas chromatography (Lab GC) instruments business; and -- Varian's gas chromatography triple-quadrupole mass spectrometry (GC-MS QQQ) instruments business.

SOURCE Varian, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Start of Phase I/II Gene Therapy Clinical Trial fo...
S
State Senate Fails Idahoans Struggling With High H...